China Pharma Holdings (CPHI) Total Liabilities (2010 - 2026)

China Pharma Holdings' Total Liabilities history runs 17 years deep, the most recent figure standing at $8.1 million for Q1 2026.

• Quarterly Total Liabilities rose 12.04% year-over-year to $8.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.1 million (up 12.04% YoY) and the FY2025 annual result came in at $8.3 million, up 15.69% from the prior year.
• Total Liabilities was $8.1 million for Q1 2026 at China Pharma Holdings, down from $8.3 million in the prior quarter.
• Across five years, Total Liabilities topped out at $15.7 million in Q1 2022 and bottomed at $6.9 million in Q2 2024.
• A 5-year average of $9.8 million and a median of $8.3 million in 2025 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2022 — Total Liabilities increased 23.83% — and 2024, when it tumbled 39.63%.
• China Pharma Holdings' Total Liabilities stood at $13.5 million in 2022, then plunged by 33.2% to $9.0 million in 2023, then slipped by 20.8% to $7.1 million in 2024, then grew by 15.69% to $8.3 million in 2025, then fell by 1.7% to $8.1 million in 2026.
• Business Quant data shows CPHI's Total Liabilities at $8.1 million in Q1 2026, $8.3 million in Q4 2025, and $7.5 million in Q3 2025.